Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT01280643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression
Study identification
- NCT ID
- NCT01280643
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Interventions
- fluorouracil Drug
- leucovorin calcium Drug
- oxaliplatin Drug
- irinotecan hydrochloride Drug
- bevacizumab Biological
- cetuximab Biological
- capecitabine Drug
- mutation analysis Genetic
- gene expression analysis Genetic
- laboratory biomarker analysis Other
- immunohistochemistry staining method Other
- nucleic acid sequencing Genetic
- protein expression analysis Genetic
- polymerase chain reaction Genetic
- DNA analysis Genetic
Drug · Biological · Genetic + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Jun 30, 2013
- Completion
- Apr 30, 2014
- Last update posted
- Mar 14, 2021
2010 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01280643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01280643 live on ClinicalTrials.gov.